Home › Rxi Pharmaceuticals: One Undervalued Biotech That Keeps Building Its Pipeline For Future Value
 

Keywords :   


Rxi Pharmaceuticals: One Undervalued Biotech That Keeps Building Its Pipeline For Future Value

2015-05-02 15:52:22| Biotech - Topix.net

Multiple collaborations between the sd-rxRNA technology and other biotech platforms provide reduced future risk along with validation of the platform. Further positive results in scarring allow the possibility to branch into other skin areas such as Pulmonary Fibrosis and Liver Fibrosis both of which are huge markets.

Tags: future value building biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »